Wei Xia ANG

Wei Xia ANG holds a Ph.D. in Biological Sciences from National University of Singapore (NUS) and is currently overseeing regulatory compliance at Cytiva. Her previous roles include serving as a drug reviewer and regulator at the Health Sciences Authority (HSA) of Singapore, a regulatory affairs manager at a clinical-stage biotechnology company, and a scientist at the Agency for Science, Technology and Research (A*STAR) in Singapore.

At HSA, she was responsible for reviewing clinical trials and marketing authorization applications for a range of products, including chemical drugs, biologics, cell therapies, and gene therapies. She also provided scientific and regulatory consultations to support the development of therapeutic products and cell, tissue, or gene therapy products.

During her tenure at A*STAR, her research focused on stem cells, cancer, and immunotherapies, resulting in over 10 publications and a patent. At the biotechnology company, she led and managed international regulatory strategies and medicinal product authorization submissions.